Tarsus Pharmaceuticals (TARS) Competitors $40.96 -0.21 (-0.51%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$40.96 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. ELAN, VRNA, LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, and ADMAShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Elanco Animal Health (ELAN), Verona Pharma (VRNA), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Its Competitors Elanco Animal Health Verona Pharma Legend Biotech TG Therapeutics Grifols Lantheus Telix Pharmaceuticals Limited American Depositary Shares Nuvalent Axsome Therapeutics ADMA Biologics Elanco Animal Health (NYSE:ELAN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership. Do analysts recommend ELAN or TARS? Elanco Animal Health currently has a consensus price target of $15.17, suggesting a potential upside of 6.43%. Tarsus Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 62.76%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elanco Animal Health 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to ELAN or TARS? In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Elanco Animal Health. MarketBeat recorded 6 mentions for Tarsus Pharmaceuticals and 4 mentions for Elanco Animal Health. Tarsus Pharmaceuticals' average media sentiment score of 1.56 beat Elanco Animal Health's score of 0.40 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community believe in ELAN or TARS? Elanco Animal Health received 89 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. However, 67.90% of users gave Tarsus Pharmaceuticals an outperform vote while only 54.96% of users gave Elanco Animal Health an outperform vote. CompanyUnderperformOutperformElanco Animal HealthOutperform Votes14454.96% Underperform Votes11845.04% Tarsus PharmaceuticalsOutperform Votes5567.90% Underperform Votes2632.10% Is ELAN or TARS more profitable? Elanco Animal Health has a net margin of 4.60% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Elanco Animal Health's return on equity of 6.78% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Elanco Animal Health4.60% 6.78% 3.03% Tarsus Pharmaceuticals -103.64%-55.86%-39.28% Do insiders & institutionals believe in ELAN or TARS? 97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 0.9% of Elanco Animal Health shares are owned by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, ELAN or TARS? Tarsus Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElanco Animal Health$4.43B1.60-$1.23B$0.7419.26Tarsus Pharmaceuticals$233.67M7.36-$135.89M-$2.73-15.00 Which has more risk and volatility, ELAN or TARS? Elanco Animal Health has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. SummaryTarsus Pharmaceuticals beats Elanco Animal Health on 10 of the 19 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.72B$3.09B$5.57B$8.62BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-10.7533.3227.1120.06Price / Sales7.36469.84409.88157.10Price / CashN/A168.6838.2534.64Price / Book6.883.457.064.70Net Income-$135.89M-$72.35M$3.23B$247.88M7 Day Performance-7.12%6.23%2.88%2.66%1 Month Performance-7.33%16.53%9.04%6.40%1 Year Performance25.11%-16.90%31.40%14.07% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals2.3744 of 5 stars$40.96-0.5%$66.67+62.8%+25.6%$1.72B$233.67M-10.7550Positive NewsELANElanco Animal Health1.1137 of 5 stars$13.94+0.3%$15.17+8.8%-22.3%$6.92B$4.43B34.859,800Positive NewsVRNAVerona Pharma2.3658 of 5 stars$84.64+0.4%$82.13-3.0%+573.5%$6.86B$118.54M-44.0830Trending NewsAnalyst ForecastAnalyst RevisionLEGNLegend Biotech3.0745 of 5 stars$34.78-0.6%$76.20+119.1%-17.3%$6.39B$728.30M-36.611,070Trending NewsShort Interest ↑Analyst RevisionTGTXTG Therapeutics2.9618 of 5 stars$39.84-0.5%$40.80+2.4%+137.3%$6.32B$386.39M-398.36290Positive NewsAnalyst RevisionGRFSGrifols3.6544 of 5 stars$8.83+0.1%N/A+28.4%$6.07B$7.21B7.5526,300LNTHLantheus4.4964 of 5 stars$83.22+2.0%$132.67+59.4%-0.4%$5.76B$1.54B13.85700Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.91+0.8%$22.00+30.1%N/A$5.67B$783.21M0.00N/APositive NewsNUVLNuvalent2.4074 of 5 stars$76.08-2.5%$115.50+51.8%-2.7%$5.60BN/A-21.9340Positive NewsAXSMAxsome Therapeutics4.6999 of 5 stars$109.87-1.8%$172.80+57.3%+52.1%$5.41B$432.16M-18.34380Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionADMAADMA Biologics2.1869 of 5 stars$20.87+1.3%$24.25+16.2%+108.3%$4.98B$459.38M74.54530Trending NewsInsider TradeAnalyst Revision Related Companies and Tools Related Companies Elanco Animal Health Alternatives Verona Pharma Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Grifols Alternatives Lantheus Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives ADMA Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
